Reuters - A heated three-year safety debate about a GlaxoSmithKline Plc diabetes pill reaches a climax this week as opponents and backers face off at a U.S. meeting that will help decide the drug's fate.
Source
Reuters - A heated three-year safety debate about a GlaxoSmithKline Plc diabetes pill reaches a climax this week as opponents and backers face off at a U.S. meeting that will help decide the drug's fate.
Source